0001828182-22-000046.txt : 20220708 0001828182-22-000046.hdr.sgml : 20220708 20220708070322 ACCESSION NUMBER: 0001828182-22-000046 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220707 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Material Impairments ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220708 DATE AS OF CHANGE: 20220708 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Signify Health, Inc. CENTRAL INDEX KEY: 0001828182 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40028 FILM NUMBER: 221072816 BUSINESS ADDRESS: STREET 1: 800 CONNECTICUT AVENUE CITY: NORWALK STATE: CT ZIP: 06854 BUSINESS PHONE: (203) 541-4600 MAIL ADDRESS: STREET 1: 800 CONNECTICUT AVENUE CITY: NORWALK STATE: CT ZIP: 06854 8-K 1 sgfy-20220707.htm 8-K sgfy-20220707
0001828182false00018281822022-07-072022-07-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 7, 2022
Signify Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
001-40028
85-3481223
(State of Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
800 Connecticut Avenue
Norwalk, CT
(Address of Principal Executive Offices)
06854
(Zip Code)

Registrant’s telephone number, including area code: (203) 541-4600

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbolName of each exchange on which registered
Class A common stock, par value $0.01 per ShareSGFYNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act




Item 2.05. Costs Associated with Exit or Disposal Activities.

On July 7, 2022, the Board of Directors of Signify Health, Inc. (“Signify” or the “Company”) approved a restructuring plan to wind down the Company’s Episodes of Care Services (“ECS”) segment. The Company’s Caravan Health business will not be impacted. This decision was made in light of recent retrospective trend calculations released by the Center for Medicare & Medicaid Innovation that lowered target prices for episodes in the Medicare Bundled Payment for Care Improvement Advanced (“BPCI-A”) program, and which the Company believes have made the program unsustainable. The Company currently expects to incur restructuring charges in the range of $25-$35 million primarily comprising severance and related employee costs to be recorded primarily in the second half of 2022. The Company may also incur additional restructuring costs comprising contract termination and facility closure costs, the amount and timing of which cannot be estimated at this time. The Company expects the majority of the restructuring plan and the cash expenditures associated with these actions to be completed in 2022.

There are approximately $85 million of annualized direct ECS costs which will be eliminated. In addition, there are approximately $60 million of annualized shared costs currently allocated to the ECS segment, of which the Company expects to eliminate approximately $30-$35 million in annualized costs by the end of 2022 as it winds down the BPCI-A program.

Item 2.06. Material Impairments.

As a result of the restructuring plan described in Item 2.05 above, the Company expects to record a non-cash impairment charge of its goodwill and intangible assets in the range of $450-$530 million.

Item 7.01. Regulation FD Disclosure.

On July 8, 2022, the Company issued a press release announcing the restructuring plan described above. A copy of the press release is furnished as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

The foregoing description and the other information provided pursuant to this Item 7.01, including Exhibit 99.1, is “furnished” and shall not be deemed “filed” with the Securities and Exchange Commission (the “SEC”) or incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in any such filings.

Item 8.01. Other Events.

During the second quarter of 2022, the Company received a semiannual BPCI-A reconciliation from the Center for Medicare and Medicaid Services (“CMS”). Within that reconciliation, CMS applied a negative price adjustment to the benchmark prices against which savings are measured for specific episodes under the BPCI-A program. Several BPCI-A participants, including the Company, disputed the price adjustment and CMS has since asked participants to provide evidence of the pricing errors. The Company is in the process of responding to the request, and upon receipt of the Company’s submission, CMS will deem the reconciliation period to remain open. The Company does not anticipate materially changing its current revenue estimates until there is further resolution or clarity of this matter. As of March 31, 2022, the Company had recorded $45.2 million and $20.0 million in revenue related to performance periods beginning in April 2021 and October 2021, respectively, that may be impacted in the event a negative price adjustment prevails. Changes in the Company’s estimates of prior period performance could result in the reversal of revenue and a further loss may be recorded. CMS has indicated it will respond to error notices prior to the fourth quarter of 2022.

Certain statements in this Current Report on Form 8-K are forward-looking statements including, but not limited to, statements related to the expected costs and impairment charges associated with the restructuring plan described above and the risk that revenue previously recorded may be reversed. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results, including the estimates described in this Form 8-K, and timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties



which include, without limitation, risks associated with a reduction-in-force and re-allocating and/or repurposing assets to other parts of the Company. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC, and the Company’s subsequent quarterly and current reports filed with the SEC.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.Description
99.1
104Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 104



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


SIGNIFY HEALTH, INC.
Date: July 8, 2022By:/s/ Steve Senneff
Name: Steve Senneff
Title: President & Chief Financial and Administrative Officer




EX-99.1 2 exhibit991pressrelease0708.htm EX-99.1 Document
Exhibit 99.1
signifyhealthlogoa.jpg
PRESS RELEASE

Signify Health focusing on fast-growing home and community services and total cost of care provider enablement

Changes expected to have positive impact on 2023 earnings

Company ending its participation in the BPCI-A program to focus on supporting future growth


DALLAS & NEW YORK – July 8, 2022 – Signify Health, Inc. (NYSE: SGFY) today announced that it is winding down its Episodes of Care Services (ECS) segment in order to focus on its fast-growing and profitable Home and Community Services (HCS) business and recent Caravan Health acquisition. The Company is exiting CMS’ Bundled Payments for Care Improvement-Advanced (BPCI-A) program in light of the newly released CMS retrospective trend calculations that lowered target prices for episodes, thereby reducing the opportunity for savings. This strategic and timely decision allows the Company to invest more to drive the future growth and diversification of the HCS and Caravan Health businesses supporting the needs of health plans and providers in total cost of care contracts, where they take responsibility for the cost of a patient’s healthcare over the course of a year. The Company anticipates these changes will have a positive impact on 2023 earnings, and will provide additional guidance in its Q2 earnings report in early August.

“Our HCS segment is experiencing tremendous growth as our health plan clients have prioritized access to the home as part of their focus on closing clinical, behavioral, and social care gaps,” said Kyle Armbrester, Signify Health CEO. “Clients are seeing the value in our unique position: our ability to see patients in the home and refer them to care for the urgent needs we identify. This is particularly so with the social and behavioral needs that are crucial to improving care but are often very hard to assess in traditional care settings. We are making investments to create operational improvements that will increase efficiency, expand use of connected devices, and allow us to diversify into new services to drive better health outcomes in the lives of people we touch.”

The Company’s timing and decision to terminate its participation in the BPCI-A program is driven by recent policies implemented by the Center for Medicare & Medicaid Innovation (CMMI) affecting BPCI-A pricing that the Company and its clients believe have rendered the program unsustainable. The BPCI-A pricing methodology has changed repeatedly over the years and has recently included the imposition of a retrospective adjustment that is not based on publicly available data, cannot be accurately forecasted, and is known only long after a performance period has ended, making it impossible to take real-time action. The Company is currently in the process of contesting the most recent pricing calculations through CMMI’s standard appeals process and advocating for CMMI to offer providers immediate relief.

In addressing the decision to end Signify Health’s participation in the BPCI-A program, Mr. Armbrester said, “We made this decision in partnership with our clients, who have repeatedly surpassed benchmarks for quality care and operational improvements with our support—including significant reductions in readmissions and increases in healthy days at home during an extremely challenging period for healthcare.”




signifyhealthlogoa.jpg
The Caravan Health business is not impacted by these changes. Caravan Health was acquired by Signify Health in March 2022 for its strong capabilities in enabling providers and accountable care organizations (ACOs) to excel in population health management and value-based payment programs. Since the acquisition, this business has continued to outperform as clients align themselves with CMS’ goal of having all Medicare beneficiaries in an accountable relationship with their health care provider by 2030, and recognize the benefits of leveraging Signify’s diverse capabilities in managing the cost for all of the care provided to a patient. This includes the Company’s post-acute and transition to home capabilities, as well as key services from its HCS segment, such as the ability to reach patients in their home in order to better manage their care, which the Company believes will result in incremental savings in 2023.

The Company currently estimates that restructuring charges for severance and employee-related costs will be approximately $25-$35M. There are approximately $85M of annualized direct ECS costs which will be eliminated. In addition, there are approximately $60M of annualized shared costs currently allocated to the ECS segment, of which the Company expects to eliminate approximately $30-35M in annualized costs by the end of 2022 as it winds down the BPCI-A program. "These cost reductions will be positive for unlocking future earnings given projections for ECS performance, where future losses would have exceeded the stranded costs,” said Steve Senneff, Signify Health’s President, Chief Financial and Administrative Officer. “We are de-risking Signify’s financial profile and driving capital allocation within the Company to support future growth and create more visibility, increased margins, and stronger free cash flow going forward.”

Signify Health will host a conference call today, Friday, July 8, 2022 at 8:30 a.m. ET to discuss the announcement. The call can be accessed by dialing (844) 200-6205 for U.S. participants, or +1 (929) 526-1599 for international participants, and entering access code 293329; or via a live audio webcast that will be available on the investor relations website event page or by using the following link: https://events.q4inc.com/attendee/105951760. A replay will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 60 days

About Signify Health

Signify Health is a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare provider networks to create and power value-based payment programs. Our mission is to transform how care is paid for and delivered so that people can enjoy more healthy, happy days at home. Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination and cost-savings. Through our platform, we coordinate what we believe is a holistic suite of clinical, social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost, all while shifting services towards the home. For more information on how we are taking health homeward, visit us at signifyhealth.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements. These statements may be preceded by, followed by or include the words “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of



signifyhealthlogoa.jpg
these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, include the plan to wind down our Episodes of Care Services segment, projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include: our ability to implement our plan to wind down our Episodes of Care Services segment and realize the anticipated cost savings and positive impact on 2023 earnings; the estimated costs associated with the plan; the impact the plan will have on our operations; the impact of CMMI’s semi-annual reconciliation will have on our estimated revenues for the performance periods beginning in April 2021 and October 2021; our failure to maintain and grow our network of high-quality network providers; the COVID-19 pandemic and whether the pandemic will continue to subside in 2022; our ability to realize synergies from the acquisition of Caravan Health, Inc.; factors beyond our control that could impact our ability to complete IHEs; our dependence upon a limited number of key customers; our dependence on certain key government programs including BPCI-A; risks associated with estimating program size and savings rate in BPCI-A; our failure to continue to innovate and provide services that are useful to customers and achieve and maintain market acceptance; our limited operating history with certain of our solutions; our failure to compete effectively; the length and unpredictability of our sales cycle; seasonality that may cause fluctuations in our sales, cash flows and results of operations; the information we provide to, or receive from, our health plans and providers could be inaccurate or incomplete; the risk that the cost of services provided will be higher than benchmark prices in our episodes and care redesign solutions; risks that arise from operating internationally; failure of our existing customers to continue or renew their contracts with us; failure of service providers to meet their obligations to us; our failure to achieve or maintain profitability; our revenues not growing at the rates they historically have, or at all; our failure to successfully execute on our growth initiatives, business strategies, or operating plans, including growth in our Commercial Episodes business; our failure to successfully launch new products; our failure to diversify sources of revenues and earnings; changes in accounting principles applicable to us; incorrect estimates or judgments relating to our critical accounting policies; increases in our level of indebtedness or in interest rates; our failure to effectively adapt to changes in the healthcare industry, including changes in the rules governing Medicare or other federal healthcare programs; our failure to adhere to complex and evolving governmental laws and regulations; our failure to comply with current and future federal and state privacy, security and data protection laws, regulations or standards; our employment of and contractual relationships with our providers subjecting us to licensing or other regulatory risks, including recharacterization of our contracted providers as employees; adverse findings from inspections, reviews, audits and investigations; inadequate investment in or maintenance of our operating platform and other information technology and business systems; our ability to develop and/or enhance information technology systems and platforms to meet our changing customer needs; higher than expected investments in our business including, but not limited to, investments in our technology and operating platform, which could reduce our profitability; security breaches or incidents, loss or misuse of data, a failure in or breach of our operational or security systems or



signifyhealthlogoa.jpg
other disruptions; disruptions in our disaster recovery systems or management continuity planning; our ability to obtain, maintain, protect and enforce our intellectual property; our dependence on distributions from Cure TopCo, LLC to fund dividend payments, if any, and to pay our taxes and expenses, including payments under the Tax Receivable Agreement; the control certain equity holders that held an ownership interest in Cure TopCo, LLC prior to our IPO have over us and our status as a controlled company; our ability to realize any benefit from our organizational structure; risks associated with acquiring other businesses including our ability to effectively integrate the operations and technologies of the acquired businesses; and the other risk factors described under “Risk Factors” in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which are available free of charge on the SEC's website at: www.sec.gov.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

# # #

Source: Signify Health

Investor contact: Jason Plagman, investor.relations@signifyhealth.com

Media contact: Lynn Shepherd, lshepherd@signifyhealth.com







EX-101.SCH 3 sgfy-20220707.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sgfy-20220707_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 sgfy-20220707_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 signifyhealthlogoa.jpg begin 644 signifyhealthlogoa.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0!:17AI9@ 34T *@ @ !0,! 4 M ! 2@,# $ ! %$0 $ ! 0 %$1 0 ! .PU$2 M 0 ! .PP 8:@ "QC__; $, @$! @$! @(" @(" @(#!0,# M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP, M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# P,#/_ !$( .D"Y ,!(@ "$0$#$0'_ MQ ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0# M!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*" M"0H6%Q@9&B4F)R@I*C0U-C+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$! M 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G< M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J" M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@ , P$ A$#$0 _ /W\HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;^_ATNPFNKAUC@MXVE MD<]$51DG\ *F4HQBY2=DMV!\\?MJ?'G4/!OB31=&T&^DL[RQ8:AF+:W'EV/B"W3,]KGY9@.LD>>H]1U7W')^-?B-X MSF^(7CK5=:N-V_4+AI5!/W$Z(O\ P%0!^%9ND:O=:#J<%Y97$MK=6KB2*6-M MK1L.A!K_ #YH_2"S7!\7XG-Z;=3"596]DWI[./NQD:PT5GXBC7 _ACOP/XD]']5_$<9 ]DK^Y^%^*< MMXAR^&9Y74YZN\Y6=CEF8\EB2>37SW_P4 M0UUEM_"^FJWR.T]S(ON-BH?U>OR[QDSIY5P;F&*IO5PY%W_>-4[KS2E?Y'?A MDY2CS;GS%1117^6Q[!);7,EE#\CT*Q5LC@CD$=J^^\/O$3-.$?:2^S):KS3:>=2FIJS/TTHKYJ_9?_:^^T_9_#OBVYQ)Q'9ZE M(WW^P24^OHYZ]_4_2N:_TEX(XZROBK+EF&63OTE%_%"7\LE^3V:U3/+J4W!V M84445]B9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y'^V=^V'X<_8Q^$ M5QXBUIENM2N-T&D:6C[9M2N,<*/[L:Y!=\84>K%5.E*E.K-4X*[9ABL52P]* M5>L^6,5=MG+_ /!0K]O31_V)OAAYJ?9]1\::S&R:-IC-QGH;B8#D0H?H7/RC M'S,OR)_P1/\ >L?'C]I#QS\9/%ES<:MJ&GQFUCO+CEI;RYYD93T&R%=FT8 M690!@ #X4^.?QP\1_M%_$_4_%WBJ^:^U;5)-S8R([=!]R*-?X8U' 'XG)))_ M8[_@D'\*?^%6_L)^%7DB\J\\3//KEQQC=YS[8C^,$<-?68S!QR[+W%?'.R;_ M !:7ET\S\LRG-:G$&?1J/2C13E&/GLF_.[OY6LNK?TY7R3_P4(E8_$G1$YVK MIFX#W,KY_D*^MJ^8?^"AWAYQ=>&]65 M!L2Z?V94Y/TYXK]4S]BPK_>'S31117^;9Z@4444 %?0O[+_[73>&/L_AWQ5< M-)IO$=I?NGJFGJ14IJ:LS],H9EN(5DC99(Y &5E.58'H0:=7R!^RE^U%-X!OX/#VOW# M2:#,P2WGG/_/,]Q_#UZ9KZ_5@Z@CD'D$=Z_P!*/#GQ$R[B_+/KV"]V M<;*I3;UA+]8O[,NJ[--+RJM-P=F%%%%?H!F%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M51\2^)+'P=X=OM6U2ZAL=-TNWDN[JXE.$@B12SNQ] H)_"A7>B%*22N]CD?V MD?VC/#/[+/PGU#Q=XHNO)L;,;(($(\^_G(.R")3]YVP?8 %C@ D?A=^U=^U/ MXF_:\^+EYXK\23;=^8;"QC8F#3+<$E8D_/+-U9B2?0==_P %!/VV=5_;2^-% MQJ7F7%KX3TEGM]!T]S@0PYYF<=/-DP&;K@;5R0H)\&K]&R3*%A8>TJ?&_P / M+_,_ .,N*I9G6^KT':C%Z?WGW?EV7SWV%4NP &2> !WK^CSX7^$H_ 'PT\.Z M#&BQQZ+IEM8(JCA1%$J #_OFOYU?!K1KXOTHRE5C%Y"7)Z ;QFOZ1J\OBV3_ M '4?7]#Z/PMIJ^)J=?<7_I05Q/[07PL_X6_\+[[28PGVY<7%DS' 69>@SVW ME<]@U=M17YWG&4X;,\#5R[&1YJ=6+C)>35G;L^SZ/4_7HR:=T?FC?V$VE7TU MK02VUU;N8Y8I%*O&PZ@@U_F'XD>&N9\(9@\-BUS M49-^SJ):379]I+[4>FZNFF_6I55-71!1117YR:A1110 5]??L1?&E_&GA23P MWJ$QDU'14#6[,?FFMN !]4.!]"OH:^0:ZSX'^/V^&?Q3T?5]Y2"&<1W./XH7 M^5_R4D_4"OTSPDXVJ\,<24,9S6HS:A571PD[-^L7:2]+;-F5:GSQL?H110#D M45_J0>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 5\!_\ !=K]J"3P+\+=&^&>EW#17WBX M_;M4*-AEL8FPD9]I)1V[0,#PU??E?A7_ ,%3OBS)\7?VY_'5QYS26NAW8T*U M4G(B6U'E.![&82M]7->]P[A56Q:E+:.OSZ?Y_(^'X_S.6$RMTX/WJCY?EN_P M5OF?/=%%%?HQ_/X X-?T3_L]_$^'XT_ OPCXLA9&7Q!I-M>N%.=DCQJ9$^JO MN4^ZFOYV*_2S_@AY^VS9V-A)\&_$5TMO(TTEYX;GE?"R%_FEM!GHV[=(@_B+ M2#KM!^;XFP_Z'Z#X=YM#"X^6'JNRJI)?XEM]]VO6Q^EE%%%?G MY^[A7E7[1W[,EC\:-/:^L_*L?$4"8CN,82Y Z))_(-U'N.*]5HKP^(N&\NSW M 3RW-*:J4I[I[I]&GNI+HUJ5&3B[H_-GQ+X:OO!^N7&FZE:RV=]:OLEBD&"I M_J#U!'!'(JC7WE\?/V>M+^.&B?O-MGK-LI%K>A>1WV/_ 'D/YCJ.X/Q%XU\% MZE\/?$UUI.JV[6]Y:-M9>JL.S*>ZD<@U_G#XJ>$V8<'8SF=ZF%F_@5_KEP?BIXG(<%B:OQ3HTI/U<(M M_F>+4TDT%%%%?1$A1110 445^ZEX\UK M08H6U:<:NFFVUI)+$LRQ(?)E,C"-T+'"@%L:EX"U?Q$LJZ3=?VPFI6US-'&TIBD/DPF,LB/M.&!8!>"17Z M14 %%%% !1110 4444 %%%% !1110 4444 %%%% !17YE?M[_P#!RQX3_8U_ M:3U_X;Z+\-M2\=W?A6;['JE^VMIID"7(4%XHQY,S/L)VLQV_,K @ GJ_P#@ MF+_P<$^$_P#@HI\>1\.+OP'J7@/Q)>VDUWI9;54U*VO_ "4WR1[Q%$R2",,X M&T@A&Y!P"!8_0JBBB@ HKX9_;>_X."O@'^QGKU[X=@U"^^(GBZQI MVVJ@?3G'J:!V9^VU%>$_\$Y?V[-%_P""BW[+FE?$K1M*N=!:YN)K#4-,GF$[ M6%U$1O02 *)%*LC*VU25<9 .0/=J!!1110 4444 %%%BVC\R=TC7.R-20"['"@$@9(R0.: .PHKXK_X)W?\%S_A M9_P4>^,U]X#\,Z#XS\.Z]:Z=)JD(UBWMQ#=Q1NBN%:*5R''F*<, " >=$!@DDMTP"0 ?3U%> M,_L&_MR^$/\ @H9^S[:_$3P7;ZQ8Z;+>3:?/::I"D=U:7$6W9+J&JW5R[?WF>9F)_6OZ.*_G)^,'A^3PG\6O%&E3+LFTW5[NT=?[K1S.I M'YBOL.$[SP_:\O_ &W_ ()SM%%%?:'X^%2V5]-IE[#<6\TM MO<6[K)%+&Q5XW!R&4CD$$9!'2HJ* /U<_P""8_\ P5GA^+ T_P"'_P 3KZ*U M\4?+;Z7K4I"1ZP>BQ3'HL_8-TDZM-KW3]N;X4Q^$/'=OK]G%Y=IKX8S MA1\JW"XW'VW @^Y#&O"Z_P J^,N%\3P[G.(R;%:RI2LG_-%ZQE_V]%I^6W0] MBG-2CS(***ZSX&^ &^)OQ3T?2?+9[>6<27./X84^9_S4$?4BO'RO+:^88RE@ M<,KU*LHQBO.327XL)KIJ , M"BO]>*W=W"BBO-?BK^V7\(_@9?2VGC/XH?#_ M ,+7L/+VNJ>(+6UN!_VR=PY^@%=HCTJBO#O"G_!3/]G?QM?BUTSXX?"NXN6X M6)O$UI$[_P"Z'<%OPS7M.EZI:ZWIT-Y97%O>6ER@DAG@D$D\+^,GM+_ $S4]*TJ>]MY0+2&)XV: M)6"2+)&X*-@X ;&&!K^CBFS7$=NNZ1UC7IECB@$?S>_\$*?V#/BYJ'_!2/X> M>)K[X?\ B[0?#/@^ZFU+5-4U729[*U@5;>54C#R*H:1W9%"+EN2V-JL1_2)3 M8;B.X7=&ZR+TRIS3J 8445A>/_BAX9^%&C_VAXI\1:%X:T_G_2=5OXK.'CK\ M\C*/UH W:*\#'_!5']FMM3^R?\+V^%/G;MF?^$EM/+ST^_OV8]\XKV+P'\2/ M#OQ4\/IJWA?7M%\2:5(Q5+W2[V*\MW(Z@21LRD_C0!M44V218D+,RJJ]23@" MDAN8[E9+''GIN8#- $E%(CB10RD,K<@CO23SI M:P/)(ZQQQJ6=V.%4#DDGL!0 ZBO$?&/_ 4K_9[\ :FUEJ_QL^%MG>*2KP?\ M)+:221$<$,JN2O\ P+%=E\(OVI_AE\?Y#'X%^(?@GQA,J>8T6C:W;7TL:^K) M&[,N/<#% '>4444 ?S,_\%D/V!_C!X:_X**_%+5X?AWXPUC0_%FNW&LZ5J>F M:1/>6EW#.?, $D:LN]-VUE)# CI@@GU'_@W7_89^*^E_\%'/#?CS6/ ?BKP[ MX5\'66HR7NH:OIDUC#(\UG-;1PQF55\R0M.&*KDA5)..,_T)37,=L 9)$C!X M!9L9I8IDG3=&RNOJIR*"KZ#J_*G_ (.4/^"I&M_LS^#=+^"_@'4IM+\4>-;! MK[7M2MWVSZ?IC,\2PQ,.4DG9),L,%43C_6 K^JU?S$?\'#/BRZ\4_P#!6_XI M1W$A:'21IEA;+_SRC73;9B!]7=V^K&@43XJKUKX)_L&_&K]H_1H]2\"_"SQU MXFTF9BD>HV6CS-9.P."!.5$9(/!^;CO5W_@G9\"M+_:8_;E^%?@76U:31/$7 MB*U@U&)6*&:V5M\T88<@M&C+DF->ZQJ>GZ39I]Z>\N M$@B7ZLQ K+\'_&7P?\0[IH/#_BOPWKDRC+1Z?J<-TR_4(Q- CI**** "BBB@ M HJ*]OH=-M)+BXFBM[>%2\DDCA40#J23P!]:Y+3/VB_A[K6JI8V?COP;=WTC M;$MX=:MI)6;T"A\D^V* .RHHS10 4444 %%5M7UFST"PDNKZZMK&UA&7FN)5 MCC0>[,0!7,:+^T/\/_$NJ+8Z=XY\'ZA>R':MO;:S;2RL?0*KDT =A1110 5_ M*+_P6$_Y2@?''_L:[O\ F*_JZK^47_@L)_RE ^./_8UW?\Q05$_JF\$_\B9I M'_7E#_Z M:E9?@G_ )$S2/\ KRA_] 6M2@D_%*__ .#DWXNVW_!1:3X>KX3\ M!?\ "!Q>.CX8\DVUS_:1M1>_9?,\_P _9YV/F_U>W/&W'-?M;7\G>L?\I9;K M_LK;_P#IY-?UB4%,*_%7_@[[_P"/G]GO_=\1?STNOVJK\5?^#OO_ (^?V>_] MWQ%_/2Z!1W/HC_@UE_Y1GZA_V.NH_P#I/:5^D5?F[_P:R_\ *,_4/^QUU'_T MGM*_2*@);A17-^,/C+X/^'EVMOX@\5>&]#GDY6/4-3AM7;Z!V!K4\,^+M)\: M::M[H^J:?JUFWW9[*Y2>,_1E)% C0HHHH **** "BBB@ HHHH **** "OPU_ MX*P_"*3X1?MT>,T\DQV?B25-?M&(_P!:MR-TK?\ ?\3#_@-?N57PK_P7+_9; ME^)WP5TWXB:3:M-JG@=FCU (N6DT^0C+'N?*DPWLLDA/ KW>'L4J.+2EM+3Y M]/\ +YGQ/'V5RQ>5N=-7E3?-\MG^#O\ (_)&BBBOT<_GT**** "BBB@#]#O^ M"2G_ 4YO/#&O:7\*_B%J1N-$NRMIH&J7+YDT^4X"6LC'K"WW4)Y0X7[A&S] M2J_FG5BK9'!'(([5^V__ 2@_;#F_:N_9R2WUFX\[Q;X-9--U-V;+W<97]Q< MGW=596/=XW/ (%?$\297&G_M5):/=>??Y]3]D\/N)IUO^$S%.[2O!O=I;Q^6 MZ\K]D?4-%%%?(GZH>9_M>>$E\5_ ?6/E#3::%OHB1]TH?F_\<+C\:^%Z_1+X MO1K+\)_$ZN-RMI-T"#Z>2]?G;7\(_2LR^G3S["8R'Q5*33\^23L_NE;T2/0P M;]UH*^P/V)/@J_@GPG)XCU"$QZEK: 0*P^:&VX(_%SAOH%]Z\Q_9+_9F;XB: MA%XBUR%ET&U?,$+C_C_<'_T6#U]3QZU]A*-HP. . !VKZ/Z./A35A4CQ;FL+ M*S]A%[NZLZC7:VD.]W+;E;G%5OL+YA5;6=9M/#NCW6H7]S!9V-C"]Q !5FOD;_@N_X_U#X;?\$F/C)J&FNT=Q%_.>25II&=V9F8Y9B869 M2W[P ' &0O8_!FO9OV3/^"@_QB_8B\017GPX\';FTBFN+A :_G=_P"#A7XL^(/B'_P5.^(VEZMJEY=:7X5DL].TFS>5 MC!80_8H)&$:$X7=([NQ'5F/M7],^C:/:>'=(M=/L+:"SL;&%+>VMX4"1P1HH M5451P%"@ < "OY=/^"[W_*6GXS?]A*T_P#2"VH".YT'_!OE\6O$/PZ_X*F? M#?3=)U2\M-,\4S76FZM9I*P@OX39SN%D0'#;9$1U)Z,@/K7].E?RS_\ !"K_ M )2R_!?_ +"EQ_Z0W-?TH?MA?M$6?[)G[+GCSXD7T<WF2F-,_[= 2/AS_@MK_P76A_85NYOAE\,5L=6^*=S;![^^G FM?"R2*" MA:/I)>5R[M[ MK>&=4A=6E%M M*?L]ZJG/ESPG,GPGTW6I$0++>:O? M75Y>TL1?2 MW&DZM(!GR9%F9VA+8VJ\;!5)R48= 7,C\Q/^"M__ 5:U;_@I19_"V<3WFCV MND>&PNOZ!#(ZV$>M?:9A+/&I/SJ\*V[)NR4#,N20Q//_ /!$'XN>(OA7_P % M.?A-'H>J7EA;^(M;BTC4X(Y66&^MI@R/'*@.' W;ANSAE5AR!7RSK^@WWA77 MK[2]2M;BQU+3;B2UNK:="DMO*C%71E/(96!!!Z$5]!?\$A/^4G?P-_[&ZR_] M#H*/ZOJ_CY_:Y^+?B+XX?M+^./$OBC5+S5]7U#6KMI)KB5I-BB9PL:9)VQHN M%51PJ@ 5_8-7\:OQ@_Y*UXH_["]W_Z.>@F)^FW_!NQ_P %!+']C[X.?'S4 M/B!XBO5^'_A33M/U6STUI3(QOI))HA#:1L<>;/\ (I P#Y:LQ"JS#Y3_ ."B M7_!8/XN?\%$/%5['K.L77AOP(TA^Q>$],N62QBC!^4SD8-S)W+R< YVJ@.*^ M7(M8NH-(GT]+B9;&ZFCN)H Q\N22,.J.1T)42R 'L';UK]4_^"7O_!M/JG[2 M?@#3?'WQJUC6/!GAS6(ENM,T'351-6O8&&Y)II)%9;=6&"$V,[ Y/E\9!^9^ M4=6M%UN]\-ZM;W^G7EUI]]:.)8+FVE:*:%QT964@J1Z@YK^CC7O^#8W]EO5? M"S:?:Z9XTTN\:/8NIP:_(]RK8^]MD5HL]\>7CVK\+_\ @HS^Q'JO_!/?]K/Q M%\--2OO[6M]/\N[TS4A'Y?\ :-G,NZ*0KD[6'S(PR0'C;!(P2!<_63_@WT_X M+6>)?VBO&2?!'XO:O_;'B1[5Y_#'B"Z8?:M2$2[I+.X/_+241AI$D/S,(W#% MFVD_KM7\>_[(OQ;PSXBL=0+=BB3H74_[+)N4CN&-?V$ M4"D?RM_\%JOBUXA^*O\ P4T^+O\ ;VJ7FH1:!XAN='TV&65FBL;6!O*2.-2< M(,+DA<98LQY)->Q?\&SOQ:\0^#_^"F_A_P ,Z?JEY!H/BW3-1AU2P$K?9[KR MK22>-RF=N]7B7#8R 6&<,:^>O^"LO_*3'XZ?]CIJ7_H]J]A_X-Q/^4N/P[_Z M\M7_ /3;?MW?\$R/A+_P48TG1X?B1H]]-?>'S)_9VI:=>&UO+ M9)-I>/=@JR,54[75L$9&"3G^;7_@J3^S5X;_ &/_ -O7XA?#?PB=0;P[X8N+ M6*S-].)KC$EG!,VYPJ@_/(W8<8H")X7X?\1:AX3UFWU+2KZ\TW4+1M\%U:3- M#-"W3*NI#*?<&N]T7]LGXO>'-5M[ZP^*7Q%M+RU<20S1>([Q7C8="#YE='_P M3D^ 6@_M2_MP?#?X>^*#?+H'BK5A97ILYA#/Y9C=OD8@@'*CG!K]SM%_X-@/ MV7]+U6WN)K?Q_J4,+AWM;G7@L4X'\+&.)'P?]E@?<4#N=9\==>^)/[7_ /P0 M%EUW1=2O+7XC>*/ASI^M7%S8DV\]Z\:07-VL83&&N(HYD"K@'SL#BOYF68L< MGDGDD]Z_L\\*^%--\#^%=-T/1[*WT[1]'M(K&RM($VQ6T$2!(XU'9550 /05 M_++_ ,%COV,_^&'/V_/&GA6SM?LOAG5IO[?\.@+M06-RS,L:_P"S%()8?^V. M>] HGZ0?\&K_ .W;K'CS3_&7P1\5:W>:HVAVJ:]X8%Y,97@MMXBNK=&8YV*[ MP.J#@;Y3P*_8JOY*?^"9_P"U5)^Q=^W+\._B$TS0Z7I>J);ZOCHVGS@P7/'< MK%(S@'^)%/:OZU()TNH$DC=9(Y%#(ZG*L#R"#W!H"0ZOY=?^"WG[<&L?MC_M MY^-ECUJ\N_!'@_49-"\/V*SDV<4=N?*EN$0?*6FE623?C<59!G"J!_0E_P % M-OVHE_8W_82^)/C^.X%OJFEZ2]MI#9^;[?<$6]L0.^V61'('\*,>V:_DMDD: M5V9F9F8Y))R2: B?2O\ P1W\-^,/%W_!2[X/V'@F_OM-U-O$5O%-"=U[G9/>2#/H/LR!AZRCU%?HC_P %E/\ E%Q\;_\ ML6)__0EH![GXP_\ !KY(L/\ P4YW,RJJ^$=2)). !N@KZ3_X*P?\'*6H:+XK MU+X>_LYW%GML9&M;_P :O"MSYT@.&2PC8%"H/'GN&#<[% "R-^1_P4^/>N_ M:/Q2SOO%WAZ?PW+=1N5DM[:XEA:?;[R11O$?]F5L1AF,_(NTAF M^H#Q?J7@CQ]XDFU!?.75?%NI)9O*C<@H;Z5'*'C&P M$8QCBN2_:)_X)#?M*?L@>&I?$WB[X9ZY8Z+IH\^;5=,NH-2ALE7GS)&M9)#" MH_ON% /?I7]65-N(([N!XI8UDCD4HZ.-RN#P01W!H#F/YZ?^"-W_ 7E\>?L M_P#Q?\/^ /BUXFO_ !;\,]>NH[ :AJ]PUQ>^&GD(1)EG'7-(MD39';0748D: M)!V2.7S8U'94%?T4?\$OOB_<_'?_ ()Y_!WQ1?2>??W_ (7LX;N4G)FG@3R) M7/NSQ,3[F@)'O%?E3_P5_P#^#B6S_9@\2ZO\,?@K'8:[XZT]FM=5\0W $^GZ M%,.&ABCZ3W"?Q;OW<;#!$A#*OT%_P7=_;^NOV#/V(KZ;P_=?9O''CR9M T.5 M7VR6.Z-FGO%]XH^%/:26(\C(K\B?^"!'_!+JS_X*!_M!:CXI\<6LEW\-OA^\ M4U_;OD+KE])EHK0MWC 4R2X.=NQ>/,R %W.-^&G[(7[87_!8K4F\53#Q=XPT MFXE8#7/$FI_9-)C(/*VXD(0J&R-MO&0ISP.:]6\0?\&K_P"TMHWA\WEOJGPK MU:X"[OL%IK=RMP3Z9EM4BS_P/'O7]#VCZ/:>'M)M=/T^UM[&QL8E@M[:WB$< M,$:@*J(J@!5 & !5B@.8_EX^''[57[5?_ 19^-<'AW4I_$WAG[&PFF\* MZ^[7FBZG#G!:-=QC*M@CSK=P_L ^'_ /@HC^RM MKG@[4K6U7Q):PR7GAC5'4>9IE^JY0ANHCD("2+T*MG[RJ1^!_P#P0S_:PU;] MBK_@I/X5T^^EFL-%\:7P\'^(K.;Y54S2".%W!X5H;GRR6/(7S!P&- ;G]/-? MBS_P6Y_X+O\ QB^ /[2?BCX,_#>QA\!0^'1#%Y MME5BR@,P.=K,S*3DJ22N":"3^;'P5_P3W_;!_P""C<\7BI_"?Q&\:1WH\V'6 MO%.I?9X9D/\ %%-?2H'3_KGD<8'2NJ\8?\&Z/[6?A+1)+Y?A[8:LL*%WAT_Q M!8RS@ 9.$:52Q]DR3V!K^FJB@KF/Y9/V6_\ @I-^T5_P2Q^*YT)=2\26=KHD MP@U/P/XH6@_$CPGYD M-IJBM#>6,KAI]*NX\":VDQW4X(.!N1D8 !A7Q/\ \'.O[%6A_%O]C"3XNVMA M;P^,?AI/;++>(@66\TV>=8'@-FXAFMYDMY"H]76YBW?]<5]* W5S]SJ_E%_X+"?\I0/C MC_V-=W_,5_5U7\HO_!83_E*!\4/_H"UJ4$G\;+0^+IOC%Y;-KC>.VUG:6,DAU(ZEY_ M7=G?Y_G=\[M_.%P?\I2$_[*H/_3O7 M]9U!5S\\?^#?/0/VFM"^&_Q&'[1$OCZ2WDOK(^&QXPNY;C4%(2?[7@S,TPB. M;; 8[/M672?#^D>,]0!(&^>\E:WM/+@A3K) M*YX"CW)(4,P^+/VO/^"W/[1W_!2KXF3>"_A-:^)_"OAW4':*P\.^$HY9M8U" M,'[UQ<0CS6R#\R1[(@#@AL;C\Z?LM>!_B)_P4"UOX8_LX^%)&M])AU6\U1@V M6MK:6?;]IU"<#^&.WAC50>CQ1W MDT:?VMK=P@;4=:F4%[07T&HQ1K"OB"R#*CR-&N%6>-F3?L 5ED4A1AJ_2.O MY4/^"-/Q:N_@G_P5"^#&I6\GD_VAXD@T&X5N%:*_S9.&'MY^>>A4'M7]5] 2 M"BBB@D**** "BBB@ HHHH *KZOI-KK^DW5C?6\-W97L+P7$$JAHYHW!5D8'@ M@@D$'J#5BB@&DU9GX:_\%(?V$-1_8Q^+LK64%Q<>!=>E:71;TY;R>YM9&[2) MV)^^H#==P7YQK^C#XR?!KPW\?OAWJ'A7Q7IL.J:-J2;9(GX:-A]V1&ZHZGD, M.0:_%?\ ;Z_X)Y>)/V)O&/G?OM:\$ZE*5TS6 GW3R1!.!PDH'_ 7 )7HRK^@ MY)G4<1%4:S]]?C_P>Y^#\8\'SP%1XO"*]%[K^7R].SZ;/I?YWHHHKZ,_/PHH MHH *^FO^"2G[0=Q\"/VR_#MN\VS1_&3C0+^-CA29F @?TRLWE\]E9QW-?,M6 M-+U2XT34[>\M96@NK.59H9%/S1NI!5A[@@&L<30C6I2I2V:L=F7XR>$Q-/$T M]XM/[NGSV/Z4**P_ACXRC^(OPV\/>((=OE:[IEMJ*8Z;9HED&/\ OJMROR*4 M6G9G]50FIQ4X[/4\^_:F\3IX6^ _B&1GVR7EO]BC'=S*0A _X"6/T!KYF_9? M_9OG^,FMC4-022'PY8R?OG^Z;MQSY2'T_O$=!QU/'N?QO\*7?[0OQ$L?"5O( M]OH&@.MYK-TO_/5E^2%.V_82?0"3)Z 'UOP]X>L_"FB6NFZ?;QVME9H(XHD' M"@?S)ZDGDDDU_/6<\ PXUXR_M3,5? X-*G&/_/ZHFW/_ +8%H[>Z7$EO(P'.U)DC8XYPO M%>KT50'\:_Q@^$/B3X!_$S6O!WB_2+S0O$GA^Y:TOK*Y3:\3CN.S*P(96&59 M6# D$&O;/V"/^"JWQB_X)SZI<+X"UNWN/#U_-Y][X=U:(W6EW4F #)L#*T5O+;Z1RNQ[*.!05<^R/V5/^#J_X7?$(VNG_%CPCKGP]OWPCZEIQ.K: M9GN[*JK<1C_96.7']ZOTL^"OQY\%_M&^!;?Q-X#\4:+XLT&ZX2\TRZ6>-6P" M4?!RCC(RC ,.X%?Q_?$GX6^)O@WXMN-!\7>']:\,:W9G$UAJME):7$?H2D@# M8/8XP:[[]C']MWXA?L&_&*S\9?#_ %J:PN8G47VGR.S6&L0@\P7,0(#H03@\ M,I.Y2K $ _Y2T_&;_L)6G_ *06U?T@_L4_M6Z'^VY^R_X1 M^)WA^.2VL?$]H9)+21MTEC<1NT4\#'C.R5'4-@;@ P&"*_F^_P""[W_*6GXS M?]A*T_\ 2"VH")'_ ,$*O^4LOP7_ .PIJ+*UU_Z%;+7XV?\ !"K_ )2R_!?_ +"EQ_Z0W-?LM_P< MR^ 9O&7_ 2NUZ_B#%?"NOZ7JLH _A:8VO\ .Z% /<_FUK^E+_@VH^%MGX _ MX)4^%M7MXT6Z\;:OJFL7;@?,[I=/9+D^T=HG'O[U_-;7]'W_ ;'?&BS^(__ M 3&TWPW',K7WP_UW4-+N(21O1)YC>QOCKM;[2X![F-AVH"1^AU%%%!)_+S_ M ,%]OAG9_"[_ (*Q?%BVT^&."TU:YL]9"J,9ENK*":=C[M,TK?\ JX?_@D) M_P I._@;_P!C=9?^AUW?_!?WXD6?Q,_X*R?%:XL)HYK729[+1PZ'/[VVLH(I ME/NLRRK_ ,!KA/\ @D)_RD[^!O\ V-UE_P"AT&A_5]7\:OQ@_P"2M>*/^PO= M_P#HYZ_LJK^-7XP?\E:\4?\ 87N__1ST$Q/I3_@A_P#LDZ?^V/\ \%&?!/A_ M7+5+WPWH/F^(]7MW&Y+B&U 9(F'0H\[0(P/57:OZEAQ7\_/_ :;PJW[?/CN M0J-Z> +D*<= =1T_/\A7] U 2"OP'_X.SM'M[;]M3X=7R1JMQ=^"EBE<#EUC MOKHKGZ;VK]^*_!'_ (.U?^3O/AC_ -B>W_I;/0$3\IK$XO8?]]?YU_:/7\6] MG_Q^0_[X_G7]I% 2/Y./^"LO_*3'XZ?]CIJ7_H]J]A_X-Q/^4N/P[_Z\M7_] M-MS7CW_!67_E)C\=/^QTU+_T>U>P_P#!N)_REQ^'?_7EJ_\ Z;;F@.A_3-7\ MN?\ P7P_Y2X_&3_K]L/_ $V6E?U&5_+G_P %\/\ E+C\9/\ K]L/_39:4!$P M?^"*O_*5'X)_]C"O_HJ2OZJJ_E5_X(J_\I4?@G_V,*_^BI*_JJH"05^7_P#P M=%?L8_\ "YOV1](^*VDVGF:Y\+;K9?LB_/+I=RRI)G'+>5-Y+CLJO,?6OU K M$^)7P\TGXN?#O7O"NO6JWVA^)-/GTN_MVZ3031M'(OXJQY[4$G\9U?U$?\$( MOVL?^&M/^";?@B\N[G[1K_@M#X4U8DY;S+156%V/4E[9K=R3U9FZU_-W^UI^ MSIJW[)/[2OC3X;ZV&-_X1U66Q\UEV_:H0=T,X']V6)HY![.*_1#_ (-4?VII M/A]^U=XK^%5Y/C3?B%I1O[&-FZ7]D&?"CMOMWG+$=?)3TX"GL>O?\'9W[4WV M31/AK\&;&XP]Y))XLUB-3@[$WVUH#Z@L;HD'O&A^GXJ:9IEQK6I6]G9PRW-U M=RK###&I9Y78@*J@'?AG&?%-^67Y'G MB8+9QYZ;C<,DF#U6%Z![(_?S_@GC^RM;_L5_L8?#_P"&\:1K>:#I:'4Y$P1/ M?RDS73Y[@S/)MST4*.U<=_P64_Y166[ ZD:EJ0S^6!^%?J=_P0,8O_P2,^#>?^?. M_'_E3NZ_+;_@[%_Y2#^!_P#LGEI_ZFH?^G.\H*>Q M^9__ =F?%2;7OVO_ASX.6:1K3PWX4.I>7GY4FO+J5'X]2EK%SZ8JG_P25_X M+M_"[_@F_P#L@VGP_O\ X>^,-8UZXU2[U;5;ZQEME@N9I6"(5WN&^6"*%3D= M5/:L/_@ZK\*W6C?\%%?#^I2*?LNL>";-H7[;H[J\1U^HPI^C"OKG_@BU_P $ MO/V9_P!KK_@G)X#\9>*OACI.O>+)FOK/6+R2_O(WDGAO)D7*I,JC,7E'@#@B M@.@S_B+8^%/_ $2WXA?^!%G_ /%T?\1;'PI_Z);\0O\ P(L__BZ^J_\ AP_^ MR5_T1G1?_!EJ'_Q^C_AP_P#LE?\ 1&=%_P#!EJ'_ ,?H%H?*G_$6Q\*?^B6_ M$+_P(L__ (NOQC^/_P <+'Q_^U[XO^)'A6QN=&L=:\5W7B33;.X*^;9"6Z:X M2-MI(RI8#@XXK^D?_AP_^R5_T1G1?_!EJ'_Q^KWAK_@B#^RGX2\0V6J67P9\ M._;-/F6XA^T7-W7DZP6]N@ZL[L0JJ/4D"N?^//QN\._LV_! MOQ)X\\67HT_P[X5L9+^]FZMM4<(@_BD=BJ*O5F90.37\VG[3W[:7QX_X+F?M M5:;X/T2WOVT_5KPQ^'?!EC=%=/L(T!;S[ACM6214#,\\@X&[:%7"T"L?LG^T M)_P<5_LO? /4YK&W\6:GX^O[?(DC\*6'VR($=EN)&C@?/JDC"OF3Q=_P=T># M[*:0:#\%O$NI1@GRVO\ 7X+%F';(2&;'YFNB_9)_X-4OAGX(T6SOOC%XHUKQ MQKI >XTW2)CINDQ'O'O ^T2X_OAHL_W!7U_X(_X(N?LL?#ZUCAL?@EX+N%CZ M'4H9-38_5KEY"?Q- ]#\H_VV_P#@YC;]L?\ 97\;?#%O@FGAY/&%A]B_M$^+ MOMGV,B1'#^5]BCW\ITW+UZUR/_!K,[)_P4POP/XO!6H@^_\ I%H?Z5^D?_!8 MO]B/X#_!+_@F5\6O$>A_!_X6^'-8T_2HDL=2L/"UC;75K-+=0PH8Y4B#JQ:0 M#((/-?FW_P &M'_*3&]_[$O4?_1]I0'0_HKK^47_ (+"?\I0/CC_ -C7=_S% M?U=5_*+_ ,%A/^4H'QQ_[&N[_F* B?U3>"?^1,TC_KRA_P#0%K4K+\$_\B9I M'_7E#_Z M:E!)_)C!_RE(3_LJ@_].]?UG5_)C!_RE(3_ +*H/_3O7]9U!3"O MQ5_X.^_^/G]GO_=\1?STNOVJK\5?^#OO_CY_9[_W?$7\]+H%'S MM?A_\4OBQ<6ZR:A>ZA%X4L9F7F"**-+JX53Z.TUMG_KB/>OV-K\V_P#@UD0+ M_P $T-0P/O>-M0)]_P#1[,5^DE /<****!'\EOP#MUTW_@I_X*BC^5;?XI6* M)@= -6C _E7]:5?R8_!/_E*3X1_[*I9_^G=*_K.H*D%%%%!(4444 %%%% !1 M110 4444 %8_C_P!HOQ3\':AX?\ $6FVNKZ+JD1ANK2X3='*I_4$'!!&"" 0 M00#6Q13C)IW1,HQE%QDKI[H_%7_@HU_P3*UK]CW6YO$&@+=:U\.[R7$5T1NF MTEF/$-QCMGA9.C< X; /RC7])FOZ!8^*M$N]-U.SMM0T^_B:"YMKB,213QL, M,K*>""#@@U^1G_!3#_@E3??LWW-YXV\!6]SJ7@&1C+=V@S)<:!D]SR7M_1SD MKT;LQ^[R7/E6M0Q#][H^_P#P?S]3\4XPX)EA;XW *]/=QZQ\UWC^7IM\3444 M5]0?F@445):VLE]=1PPQM)-,P1$499V)P /J: /Z _V('E?]C7X4F88?_A$= M+ _W?LD>W_QW%>DZB9C:LEL56X<81F&5C_VB.^.N._3CK6+\(_!(^&?PH\,> M&U;[,>2?Z8%7J**PHT:=&FJ5)6C%626R2.@* M***U *R/'_C[1OA9X(U;Q)XBU*UT?0="M)+Z_O;E]L5K!&I9W8^@ /O6O7P] M_P '!_P(^*'[1'_!.[4-!^%MC?:Q>0ZU:7^MZ58Y:ZU338EE9HXD',K+-]GD M\L9+"(X!( (!L_LV?\%Z?V9_VG?'\GAG2_&\GAW5&E,5G_PDEJ=,@U+G ,4S MGR\MQA)&1SD *3D#['1UD0,I#*PR"#P17\7-]8SZ7?36MU#+;W-N[12Q2H4D MB=3AE93R""""#R#7L7P8_P""BOQV_9YT2'2_!OQ:\>:%I-JNR#3XM7EDLH!_ ML0.6C7_@*B@KE/Z(_P#@N;\'/AG\1?\ @G%\2M8^(5CI:W?A?1;B\\.ZI+&H MN[+4\?Z+'#)CBW.M^(-8E" M1QQJ?+MDR TTSXQ'$@.6=N /? (-:'[V?\&L3Z@W_!-+4A>>=]F7QOJ L-_W M1#]FLR=OMYOF_CFOR0_X+O?\I:?C-_V$K3_T@MJ_HV_8._9(TK]AG]D[P;\, M=)F6\7PY9D7EZ$V?;[N1FEN)L=0&E=RH))5=JY.*_G+_ ."\4;1?\%:_C,&5 ME/\ :-F<$8X.GVI'YCF@2W(?^"%7_*67X+_]A2X_](;FOZ5OVL?V?[#]JK]F MCQQ\.=298;;QAHUQIJS,N[[+*Z'RIL=S'($<#U05_-7_ ,$)HVE_X*S_ 8" MJS'^T[DX SP+&Y)_(ZY&0PX(((X-?17_ 23_P""H&M_\$Q?C_/KB64VN^"_$D4= MGXDT>.0))<1HQ,<\)/ GB+.5W<,KNI*[@R_KW_P6[_X(9Q_MX22?$SX:&QTO MXJV5L(KVSF(AMO%,4:XC5I.D=RJC:LC?*RA5$]#:2,/)9^(;D:1=6Y[HRS[0S#I\A8'L2.:\+_P""A'_!QK\&_P!G MSX::I8?"K7K/XE?$*ZA>#3QI\;2:5ITA&%GGN" DBKU"1%RQ4 E =P_G/KU# M]DC]CKX@?MN_%VQ\&?#W0;K6-1NG7[3<[&%GI<).#/21A0S$*0 M7*>>^)O$NH>,_$FH:QJUY<:AJFK7,EY>74[[Y;F:1B[R,>[,Q))[DU] ?\$A M/^4G?P-_[&ZR_P#0ZRO^"E_[)]A^PY^V5XE^%>GWTFJQ^$[+28Y[YUVF\N9M M,M;F>0+D[5,TTFUO[*J_C7^,D;0_%[Q4C*RLNL788$8(/G/03$_27_@TV_Y M/S\>_P#8@W'_ *<;"OZ Z_G]_P"#35&/[>'CYMIVKX"G!.. 3J%AC^1_*OZ MJ!2W"OP1_P"#M7_D[SX8_P#8GM_Z6SU^]U?@G_P=K1L/VN/A@VUMK>$' .." M1>S9_F/SH'$_*.S_ ./R'_?'\Z_M(K^+G3T:6_@55+,TB@ #DG-?VC4!(_DX M_P""LO\ RDQ^.G_8Z:E_Z/:O8?\ @W$_Y2X_#O\ Z\M7_P#3;>&9FM]:\-W)N+= MPVW(9&C=<]MR.R_C7]7'[>O[*UC^VM^R'XZ^&M]Y*R>)--=+">0?+:7L9$MK M*>^%F2,G')7<.]?R/^)O#=_X-\2:AH^J6LUCJ>DW,EG>6TJ[9+>:-BCHP[%6 M!!]Q05$HD[CDU_1E_P &S'[(G_"@/V"F\<:A:^3K_P 6KW^U"67$B:=#NBM$ M/LV9I@>ZW"U^"/[)/[/&I?M9?M,>"/AQI/F+>>+]7@L#*B[OLL);,TY'I'$) M)#[(:_KS\"^"M-^&O@C1_#NBVJ6.CZ!8PZ=8VZ?=@@AC6.-![!5 _"@)&K7S M-_P64_Y16G_IRU*OU(_X(%?\HC/@W_UZ:A_Z<[R@I['S1_P=2?L?7GQ3_9O\ M)_%K1K62XN_AQ=R66KK$I9AI]V4 F;VBG1!["X8G@5X!_P &NW_!0[3?A7XY MUOX"^*KZ.RL?&EY_:OABXGD"QKJ.Q8YK7)_BF1(R@R 7B91EI *_<;QAX0TO MX@^$M4T'6[&WU31]:M9;&^L[A-\5U!(A22-AW5E)!'H:_FP_X*T?\$7O'7_! M.;XBWGBGPK:ZMX@^$LMP+G3=:^W=&_X.AOV8=4TE;B=OB'ILQ7)M;C05:4'TS',Z9_X%B@5F?HM17X MT_M8_P#!V1I*Z#H+2I@]5(XKQ[ M_@AS\<_VJ/VL_P#@I3;?$.XU[Q=XG\(SO-#XUO=0E==%BMFC8I"D>5A257\L MQ1PJ"O7 3?D"Q]R?\'0/BK4O#W_!+^:TL7D6UUSQ7IMCJ(4=!" M?J!7QU_P:/Z!HEW\?_B]J=PL3>(K'0+*WL,_>%M+<.;DC_@<5L"?<>M?K-_P M4A_8[@_;P_8R\:_#1KB&SU#6;59]*NI<[+6^@=9H&8@$A"Z!&(!.QVP,U_-3 M^S9^T#\4O^"1/[:;ZM'I+O"LTFE:[H6I(R1W]LQ4RV\F.J/M1T=+M3\1?#;5A&OVBRU'2+C4(A)_$(I M;-)=Z@]&=8R?[HZ5YY^V7_P=+_"KX?\ A&^L?@QI>J^/O$\R-'::AJ%E)I^D M6I(XE=9-MQ+@\^6$3=C[ZT$V9A?\'4W[:]CX1^!WAWX%Z5=K)KGBZZBUS7(T M;/V;3X&)@1QZRW"AQZ"V.?O U\A_\&M'_*3&]_[$O4?_ $?:4SX _L+?$+]K MS]GG]H#]KOXW/J-]_P 4CJ]YX>DU!/+?6[UK1XQ=)'@!;6",[8@H"[@FSY8B M"_\ X-:/^4F-[_V)>H_^C[2@KH?T5U_*+_P6$&/^"H'QQ_[&N[_F*_JZK^;O M_@Y(_9'UCX"_\%"M9\;?8IO^$4^*4<6JV%VJ?NENDBCBNH"W3S Z"7']V=>O M. (G]%W@&=+KP+HLL;+)')80,K*F>#_AW\'_B MQX9U9]3MWL_#5AXGTUTFBFC)6"W:Z@;:RE5V*SH7+8+;0<@_L_02?R5_MA6% M]^S9_P %*?B-NCD-UX1^(5]>0!QM,RQW[S1-]'38P]F%?U1GLK":[-K?:/N)9EMYMKCRRQ+&-U(R3M9,G(5NC^E M"OQ5_P"#OO\ X^?V>_\ =\1?STNON+_@FA_P6M^''_!3;QSK7A7PWH'BKPUX MFT/3?[7FM=4CA:&>W$L<3M'+&[9*O+&"&5>'!&>&-I)&QWPJDXK^4OX)_P#*4GPC_P!E4L__ $[I7].' M[?OP;U3]H3]B3XJ^"=#^;6O$GAB^LM/3.!-<-"WEQD]@[ +GMNS05(^2_'7Q M6\)?B5KWQPT*3XO+D>%_&=OXZ\7_$;X%^(O$/_"'ZW%XVMDB\5?#? M5FNOL:_:)E1#-;B[Q!*LX,D9DC=9)$)%'B>VU#_@H9KW[+/CCP!K'BCPGI>G MV6O)KFK:$EO]L\)7K:=%";.X6XBD2.1;A'A9&3/RG!&0U<+XV\(ZAX<_X)H: M'\ =5T6[T[XS?%/QBVAW,4\CW$VOWB:NMUJ7B/8D?&%% C M])J***!!1110 4444 %%%% !1110 5''_ )KC5M!@4L^F=VFMUZM#W9!S M'U&4X3\]Z_I8K\X?^"G/_!(Y=<_M#XB?"?356^^:XU?PY;)@7/=IK51T?J6B M'#=5^;Y6^SR7/]L/BGZ2_1_Y_>?D/&' UN;'9;'3>4%^. MO ]C_P )!(,#7]*/V#5%., M-'CSL#H)@ZCL*^(?'7_!I)\,=2U$OX:^*WCK M1[4_\LM1LK74''_ D$'\J_6JB@#\I?AC_P &F?PBT#4(YO%GQ'\>^)(XVW&" MRBMM,CE']UB5E;'^ZRGW%?H-^RM^Q/\ "W]BCP:VA_#/P;I/ABUF ^TSQ*9; MR^(Z&:XD+2RXYP&8A<\ #BO5** "OE/]L[_@C!\!?V[OB:/&?CCP[J47BEX$ MMKG4=*U&2SDOHXUVQB51E&95PH;;NVA5)(50/JRB@#Y2_8R_X(N_ 3]A/XG? M\)IX(\.ZE-XJC@DM[74=5U&2\DL4D7;)Y2G"*S*2I?:6VEE! 9@?JVBB@ KE M_BC\$/!?QPTA=/\ &GA'PSXNL8\[+?6M+@OXDSUPLJL!G Z>E?#?_!?'_@K5 MXD_X)S>"?!_A[X>?V7_PGGC-YKIKJ]A%PNEV,)52XB/!>61]JELJ!%+QG!'Q M7^SU_P '97Q$\)V45G\2_AOX=\9!/E-_H]X^CW)']YT99HW;V41C^H.S/U(' M_!&W]EP:K]L_X4AX$\X/OV_8SY6[9CVQCMC%>[?#KX4^$_@GX:_LOPE MX;\.^$M'C/F&TTG3X;"V4@8W;(U5>@ZX[5^5US_P=P_#U;%FA^$/C.2YP=L; MZI;+&3[L 3^.VOCC_@H-_P ''/Q7_;.\":EX,\+Z/8_"_P ':Q$UOJ$=E=M> M:GJ$+##PO=%4"QL.&6.-202I9E)!!V9\\_\ !6_]H33/VI?^"CWQ8\;:+<1W MFC:AJZV5A"+_AIJ7QM\::OB3X^_P#!OC^S M1^T/\5M8\9:IX:US2=8\07+WNH+I&KR6UO<7#L6DE\LAE1F8DD)M4DDXR23] MMT4$'@/[#O\ P3,^$/\ P3QL=87X:^'[BROM?V+J&I7UX]Y>7*(24CWL<(@+ M$[4"@G!.2 1[]110 5X3^V__ ,$W_A+_ ,%#/#^DV7Q,\/S:A/H+R-INH6=V M]I>67F;?,570_,K;5RKAER 0 1FO=J* /AOX,_\ !NU^S#\%?B1I/BBU\,Z] MK5]HMPEW:0:OK$EQ:K,C!D=H@%$F& .U\J>ZFON2BB@#Y#_:X_X(=?L]_MH_ M%N[\=>+/#>JV?BC4E47]YI&IR6@U JH17D3E-X50-RJ"<,?''AW4H_%'D):W&HZ5J,EG)>QH,1B51E'*C@- MMW;0JDD*H'U510!\F_L4O"*S(2I?:6VLP! 9@?K*BB@ HJCXH\36'@KPSJ.LZK=0V.EZ3:RWMY M\"_\+.U&SOOA%XH3P?#*Z66J6FK0S:A< M("0KO:.D:(6&#M$[;>F30!^M'BOQ3I_@;PMJ6MZO=PZ?I.CVLM]>W4QVQVT$ M2%Y)&/95523["OY#?VQOCO'^T_\ M5?$+XA0V$6EV_C#7KO5(+6- GDQ22,4 M#8X+[=I9OXF+'O7W+_P5F_X.&]6_;I^&%U\-_AWX=U'P3X'U-E_M>[OKA&U/ M68U(98"L>4@BW#+!7, MR37,TC!4C11RS,Q '))H*2/UK_X-1/V0_\ A*_B]XV^-6IVNZS\)V__ CV MB.Z_*;VX4/<.I_O1P;$/M=FOW4KY^_X)=_L:Q_L'?L1>"OA[,L#:Y:VQO]=F MBY6;4)SYD_S?Q!"1$K=TB6OH&@3"N<^+WPGT#X[_ NU_P &^*;!=4\.^)K& M73M1M6=D\Z&12K ,I#*>,/A_ MH^L+XBOK)M.^UZEJ;W9MX'=7=8U.%4L43+$%L# (!8'ZDHHH **** /F?]N? M_@DG\&/^"A_B[1O$'Q%TG5I-2 MQKL** "H=1TZWU?3Y[2[@ANK6ZC:*:&9 \"I!((/!!J:B@#X1_:7 M_P"#D2)_6OF^]_X M-&/!;ZDS6_QH\416>[(BDT*"20+Z;Q*HS[[?PK]?J*!W9^=_[/O_ ;)_LV_ M!O5(=0U^'Q9\1[R'#"+7=16.R#CN(;9(MP_V9&<'N#7WYX+\$:+\-_"UEH?A MW2=-T+1=-C$-I8:?;);6UL@_A2- %4>P%:E% @KP3]M7_@F;\&OV_M)CC^(W MA*WO-6M8_*M-60$DB.0.F23MSS7O=% 'Y&^+O^#1_X=WNK M,^@_%WQIIMCGB&_TRVOI0/\ KHAA'_CE>R?LI?\ !M)^SY^SMXELM<\1?V_\ M4-6LB'2'7Y(ETM9 .09.'1E89.",UVE% M 'P!X%_X-KOV;?AU\:]$\:Z;'X[5] U&+4[72)M9273C)%()$5PT7G,@8#@R M\@8.><_?]%% ".BRHRLH96&"",@BOC+]H[_@@-^S#^TCKUQJUUX%D\)ZM=LS MS7/AB\;35D8G);R &MPVN7\5PT%L9$E:.-8HHE 9XXR2P8_(,$#(/;?MU_\ !-KX M5_\ !1;0?#]C\2]+U"\;PO---IEU87SVMQ;><$$J9&05?RXR00>47&.<^]44 M >8_LB_LA>!?V'O@O9^ OA[IDVFZ!:SRW;">X:XGN9Y""\LCMRS'"CL % M%>G444 %%%% 'QOH/_!!S]G'PW^TW!\5K3PQJR>(;76QXAAM#JTITZ*]$OG+ M((?[HE^<(6V @#&WY:^R*** /!_B;_P3R\$^.?B)J7B[0=7\=?#/Q1KCB36- M0\%:_-I/]LL!@/+/^P#\,C^T_#\6ET)(_$T2,YB7 LWNB1B\, M6,>>!GY@<9.[&\!J]IHHK2I6G4MSMNRLK]CGP^$HT.;V,5'F=W96NWU?F%%% M%9G0%%%% !1110 4444 %%%% !1110 4444 %%%% 'YP_P#!(?\ M@I)XK\/^/? GB32]-\7^'=)_L:33-7+QV>H6ZRRSH4E16,_X(K_ +4GP5NVCU3X,^+]313\LV@0KK:./7_1&D(^C 'U K^JFB@? M,?Q_R?L6_&2&^^RO\)?B8MUNV^2?"]\),^FWRLYKUKX,?\$4?VHOCCJ4<&F_ M!WQ7H\3X+W/B&$:+%$I_B/VHQL?HJL?:OZIJ*!\Q^57_ 3<_P"#97PG^S_X M@TWQE\:]4T_X@^([(K/;^'[6(_V'9RC!!E+@/=D$A_F5^.'_ M 2A_:,_9YUF2S\2?!_QNR1MM%YI>G/JMD_H1/;>9'SUP6!]AS7]8]% TS^3 MGX*?\$H/VCOC_K5O9^'_ (.^.DCN&"B\U33)-+L5'Y$ XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jul. 07, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 07, 2022
Entity Registrant Name Signify Health, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40028
Entity Tax Identification Number 85-3481223
Entity Address, Address Line One 800 Connecticut Avenue
Entity Address, City or Town Norwalk
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06854
City Area Code 203
Local Phone Number 541-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.01 per Share
Trading Symbol SGFY
Security Exchange Name NYSE
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001828182
Amendment Flag false
XML 8 sgfy-20220707_htm.xml IDEA: XBRL DOCUMENT 0001828182 2022-07-07 2022-07-07 0001828182 false 8-K 2022-07-07 Signify Health, Inc. DE 001-40028 85-3481223 800 Connecticut Avenue Norwalk CT 06854 203 541-4600 false false false false Class A common stock, par value $0.01 per Share SGFY NYSE true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &HXZ%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !J..A4F17/(NX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VU!)71[43PI""XHWD(RNQML_I",M/OVIG&WB^@#>,S,+]]\ M ].K()2/^!Q]P$@&T]5L1Y>$"AMV( H"(*D#6IGJG'"YN?/12LK/N(<@U8?< M([2<7X-%DEJ2A 58A97(AEXKH2)*\O&$UVK%A\\X%IA6@"-:=)2@J1M@PS(Q M'.>QAPM@@1%&F[X+J%=BJ?Z)+1U@I^2NI++.S3P]O3X4M:MC$LD MG<+\*QE!QX ;=I[\VMW=;Q_8T/*VK?A-Q6^W32-X)UK^OKC^\+L(6Z_-SOQC MX[/@T,.ONQB^ %!+ P04 " !J..A4F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &HXZ%3&B6#7900 !L1 8 >&PO=V]R:W-H965T&UL MG9AO;]LV$,:_"J$-PP8DD<38CIK9!APG:;.VJ1&[*[IA+VB)LHE(I$91_O/M M=Y1MR47ED[L7B45)]_A''OD+GG*\BN5 M<0E/8J539J"I%VZ>:N#XSN'&BU@LC;WA#OL96_ I-Y^SB8:66ZE$(N4R%TH2S>.!,_)O[VC7 M!I1O_"GX.C^Z)K8K;>,I&CB>)>()#XV58/"QXF.>)%8)./[=BSK5=]K MX^N#^F/9>>C,G.5\K)(O(C++@1,X).(Q*Q+SHM;O^+Y#)6"HDKS\3]:[=SL= MAX1%;E2Z#P:"5,C=)]OL!^(X(#@10/?5%)><\,&_:U6A-MWP8U>U%V MM8P&."%M5J9&PU,!<68X5BNN^ZX!*7O##?=A=[LP>B+LCR*Y(M[-!:$>I=^& MNT!08= *@Y9ZUQ@&^7LTSXV&1/W31+13Z#0KV-E[FV[PC?=<5WC:D/[U58P%PT9+;->!,<'AY1!1@22 MWLB#*Y7I*_/7EL!NQ=9%%1^D$69+7OA"V!0"Y#-+&\EPG:E82!%OR3O.$K.\ M($\RO$+P>A5>[QP\4%,Z4YI91[@@4P.C1Y0F8U5(H[?P&34RX^+W#PCA345X M2[2>?.JQ#4\S[_L>!X-$)Z@X@G.X9FQ#7F*8-*)6(3EL"%TN&+0 MO;SN!#ZEUPC>FPKOS3EXHRB"Q9Y?'"[(!WB/?)*-6<05 \^#_$MIRT58&#): M<5EP!-7W:H_U?@AV;%LP[69J+1N]%Y=[5GK-DE<,[3>-/)&*EPH9DF.KK_:_'W6K"DD0=7:>6IK=['?7JB M^64(P\-A?>UV%5Q&L/_Y%,%T#6"HC+M@+6MN_C M+CT3!@JDBHE/?YW_1J8\+&"^;1N9<*5QPJ!>C(CM+E0UV&F'KQ>O4VS[0X]. &?9_4/*]<*.T5M0,$MK(QF3C0EN$30: M+=^T-GN*>_6!;$,@?W >+7=!NSUX(Q:NUK86:.W]%+?M/=<8UJF&(O $2W1# MWO/FL<*E/-@Z!C2 /XRLK@$4M^X1>$=4^L=CPA:-//_3^]VCHZ[]V> CL[,E M)PF/07I=ZX,G*7+RR5G8&;V!7@>*V4.#7N@KGX/&?X' M4$L#!!0 ( &HXZ%2?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8Q MYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_* M%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2 M,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T] M.PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D M'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3 M\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_R MBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P M6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8 MLAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z M'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8 M"<:1/,<0F,7XC&894IT,/O'^8* \^ M>Q\ETWLJ.?]74_P$4$L#!!0 ( &HXZ%27BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://signifyhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sgfy-20220707.htm exhibit991pressrelease0708.htm sgfy-20220707.xsd sgfy-20220707_lab.xml sgfy-20220707_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgfy-20220707.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sgfy-20220707.htm" ] }, "labelLink": { "local": [ "sgfy-20220707_lab.xml" ] }, "presentationLink": { "local": [ "sgfy-20220707_pre.xml" ] }, "schema": { "local": [ "sgfy-20220707.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sgfy", "nsuri": "http://signifyhealth.com/20220707", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgfy-20220707.htm", "contextRef": "ib3d5a9ad0a4640dfbde03521a44911d2_D20220707-20220707", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://signifyhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgfy-20220707.htm", "contextRef": "ib3d5a9ad0a4640dfbde03521a44911d2_D20220707-20220707", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001828182-22-000046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001828182-22-000046-xbrl.zip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end